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Discovery of new polypharmacological antibacterial agents with multiple modes of actions can be an
alternative to combination therapy and also a possibility to slow development of antibiotic resistance. In
support to this hypothesis, we synthesized 16 compounds by combining the pharmacophores of Chla-
mydia trachomatis inhibitors and inhibitors of type III secretion (T3S) in gram-negative bacteria. In this
study we have developed salicylidene acylhydrazide sulfonamides (11c & 11d) as new antichlamydial
agents that also inhibit T3S in Yersinia pseudotuberculosis.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chlamydia trachomatis is a common sexually transmitted path-
ogen that can cause infertility and Chlamydia pneumoniae causes
respiratory infections and pneumonia [1]. Each year millions of
people are infected by C. trachomatis especially below the age of
twenty ﬁve [2]. These infections are treated with broad spectrum
antibiotics which affect pathogens as well as the normal endoge-
nous microﬂora and thus select for antibiotic resistance in both
populations [3]. Antibiotic resistant C. trachomatis can easily be
generated in vitro, but so far only limited amount of resistance has
been detected in patients [4]. Development of antibiotic resistance
has been suggested to be considerably slower when using multiple
antibiotics simultaneously [5], but this is not feasible in most
clinical situations with common infections, where patient, Umeå University, SE90187
. Elofsson).
Masson SAS. This is an open accesscompliance is often questionable [3,6]. However, targeting multiple
mechanisms of the disease with a single molecule would not
endanger patient compliance and could offer beneﬁts in slowing
development of antibiotic resistance. Modern drug discovery has
been strongly focused on the discovery and development of potent
and selective drugs that act on a speciﬁc target. Poly-
pharmacological approaches based on single molecules that act on
multiple targets of relevance for one or several pathways have been
suggested as an alternative strategy to ﬁnd new treatments of
diseases [7]. Unintended polypharmacology is generally associated
with side-effects and successful design of polypharmacological
drugs is one of themajor challenges in drug development. Formany
drugmolecules beneﬁcial or undesired polypharmacological effects
are discovered late and may be not even until the drug has reached
the market.
We have previously shown that salicylidene acylhydrazides
such as I (Fig. 1) are potent antichlamydial compounds with puta-
tivemechanisms including type (III) secretion system inhibition [8],
iron chelation [9], and effects on HemG in heme biosynthesis [10].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Structures of C. trachomatis inhibitors and synthesized compounds.
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additional targets for this compound class [11]. Recently, we used
phenotypic high content screening and identiﬁed acylated sulfon-
amides exempliﬁed by II (Fig. 1) and N-(phenylcarbamothioyl)-1-
naphthamides III (Fig. 1) as potent inhibitors of Chlamydiae [12].
In addition, recent literature describe urea and thiourea derivatives
as inhibitors of gram-negative bacteria [13e16]. In this study we
explore the possibility to develop novel antichlamydial agents by
combination of the identiﬁed pharmacophores from the different
classes of anti-chlamydial compounds and T3S inhibitors. With this
hypothesis we designed and synthesized ureido-sulfonamides
4aed, thioureido-sulfonamides 5aed, salicylidene acylhydrazide
sulfonamides 11aed and salicylidene acylhydrazide-cinnamoyl
sulfonamides 15aed (Fig. 1) and evaluated them for their biological
activities against Chlamydiae and T3S.2. Results and discussion
2.1. Chemistry
In compounds 4aed and 5aed we combine the ureido and
thioureido motif A from the screening hit III with the core element
B of antichlamydial compounds II (Fig. 1) [12] to explore if the
antichlamydial activity could be improved. The salicylidene acyl-
hydrazide pharmacophore D in compound I is responsible for both
iron chelation [9,17] and T3S inhibition [18] and by combination
with the core and extended scaffolds B and C in the antichlamydial
compounds II (Fig. 1) [12] we envisioned that the resulting com-
pounds 11aed and 15aed would maintain all three biological ac-
tivities. The speciﬁc building blocks and substitution patterns as
well as the positions for merging the different structural elements
were selected based on previous structureeactivity relationships
the identiﬁed positions that allow substantial structural variation
[12,18,19].
The ureido and thioureido compounds 4aed and 5aedScheme 1. Reagents and conditions: (i) 5-methylisoxazol-3-amine, pyridine, DMAP, rt, 12 h;
(iv) a: Thiophosgene, THF, 0 Cert, overnight; b: Et3N, RNH2, 1,4-dioxane, reﬂux, 12 h (forrespectively were synthesized as outlined in Scheme 1. The inter-
mediate N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl)acet-
amide 2 (59%) was obtained by reacting 4-acetamidobenzene-1-
sulfonyl chloride 1 with 5-methylisoxazol-3-amine in pyridine,
which was subjected for deacetylation with NaOH to achieve 4-
amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide 3 in 93%
yield [12]. Compound 3was then reacted with triphosgene to form
the corresponding isocyanate that subsequently was combined
with different amines to obtain the urea compounds 4aed in
16e30% yields. To synthesize the thioureido derivatives 5aed,
compound 3 was reacted with thiophosgene according to a modi-
ﬁed procedure [20] to form the isothiocyanate which was then
treated with the respective amines to achieve thioureido de-
rivatives in 14e45% yields.
Scheme 2 describes the synthetic pathway leading to the sali-
cylidene acylhydrazide sulfonamide hybrids 11aed. Compound 7
(74%) was prepared by reacting 4-bromobenzenesulfonyl chloride 6
with 5-methylisoxazol-3-amine with catalytic amount of DMAP in
pyridine. Pd-catalyzed cyanation was performed to convert 7 to 4-
cyano-N-(5-methylisoxazol-3-yl)benzenesulfonamide 8 by using
Zn(CN)2 as a CN source [21] in 36% yield and the cyano group was
then hydrolyzed to acid with KOH [22] in nearly quantitative yield.
The resulting carboxylic acid was coupled with Boc-hydrazide in
presence of EDC$HCl and DMAP to obtain the intermediate 10a in
75% yield [23]. N-Boc deprotectionwas performed by using 4MHCl
in 1,4-dioxane to obtain hydrazide hydrochloride salt (10b) in 83%
yield. The hydrazide was subjected to condensation with selected
salicylaldehydes [11,18] to obtain salicylidene acylhydrazide sul-
fonamides (11aed) in 39e55% yields.
The salicylidene acylhydrazide sulfonamides based on the
extended scaffold i.e. 15aed were synthesized as summarized in
Scheme 3. N-Acylation of 4-amino-N-(5-methylisoxazol-3-yl)ben-
zenesulfonamide 3 with acryloyl chloride and NaH gave 12 in 47%
yield and coupling of Boc-hydrazide to 4-bromobenzoic acid in
presence of EDC$HCl and DMAP [23] yielded 4-bromobenzene-Boc-(ii) NaOH, H2O, reﬂux, 4 h; (iii) Triphosgene, DIPEA, RNH2, THF, 0 Cert, 15 h (for 4aed);
5aed).
Scheme 2. Reagents and conditions: (i) 5-methylisoxazol-3-amine, pyridine, DMAP, rt, 12 h; (ii) Pd2(dba)3, dppf, Zn, Zn(CN)2, DMF, 150 C, 18 h; (iii) KOH, IPA:H2O (5:4), 100 C, 18 h;
(iv) NH2NHBoc, DMAP, EDC$HCl, DMF, rt, 12 h; (v) 4 M HCl in 1,4-dioxane, DCM:MeOH (9:1), rt, overnight; (vi) Respective salicylaldehyde, EtOH, 70 C, 4 h.
Scheme 3. Reagents and conditions: (i) Acryloyl chloride, NaH, THF, 0 C-rt, 5 h; (ii) Pd(OAc)2, dppp, TEA, DMF, 100 C, 24 h; (iii) 4 M HCl in 1,4-dioxane, MeOH, rt, overnight; (iv)
Respective salicylaldehyde, EtOH, 70 C, 4 h.
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subjected to Heck coupling by using Pd(OAc)2 as a catalyst and the
ligand 1,3-bis(diphenylphosphino)propane (dppp) [24] to obtain
intermediate 14a in 29% yield. Finally the Boc group was removed
to achieve the hydrazide 14b as a HCl salt in 90% yield. Subsequent
condensation with salicylaldehydes gave the targeted compounds
15aed in 34e54% yields.2.2. Biological activity studies
The library of sixteen compounds (4aed, 5aed, 11aed and
15aed) was investigated for their in vitro activity against replica-
tion of C. trachomatis and C. pneumoniae in HeLa cells using previ-
ously described methods [12] (Table 1). The salicylidene
acylhydrazide sulfonamide class i.e. 11aed showed promising ac-
tivity at 50 mMconcentration against both bacteria. The salicylidene
acylhydrazide-cinnamoyl sulfonamides 15aed were however less
effective with 14e33% inhibition of C. trachomatis at 50 mM con-
centration and virtually no effect on C. pneumoniae. The most
potent compound of all, 4-N,N-diethylamino salicylidene acylhy-
drazide sulfonamide 11c showed 83% and 100% inhibition respec-
tively of C. trachomatis and C. pneumoniae at 50 mM concentration.
Similarly, 3,5-dibromo salicylidene acylhydrazide sulfonamide 11d
blocked 99% of C. pneumoniae and 65% of C. trachomatis at the same
concentration. The other two compounds in the class 11a and 11b
also inhibited C. trachomatis to some extent suggesting general
antichlamydial properties of this compound class. The lower ac-
tivity of 15aed compared to 11aed may be explained by their
relatively poor aqueous solubility. The ureido-sulfonamides 4aed
and thioureido-sulfonamides 5aed showed low activity against
C. trachomatis with 10e27% inhibition at 50 mM and no activity
against C. pneumoniae. In contrast, the 4-hydroxyphenyl thioureido
derivative 5c had higher activity against C. pneumoniae with 61%
inhibition at 50 mM and no activity against C. trachomatis,highlighting possible differences in afﬁnity to the molecular targets
of these compounds in the respective Chlamydia species.
To evaluate whether the compounds affected host cells a resa-
zurin based viability assay was used. All compounds except 15c
were tested at 50 mM and well tolerated (>70% cell viability
compared to control after 48 h). Limited aqueous solubility of
compound 15c in the assay hampered its testing.
Our design aimed at including the iron chelating properties of
the salicylidene acylhydrazides (I, Fig.1) [9,17] andwe tested this by
comparing the growth inhibition of C. trachomatis of 11c and 11d as
well as the parent compound 16 (compound 18 from ref. 12) at
50 mM in presence of iron sulfate in a range from 0.08 mM to 250 mM.
As predicted addition of iron abolished the inhibitory activity of
compounds 11c and 11d against Chlamydia in a dose dependent
manner, while acylated sulfonamide 16 that lacks iron chelating
properties was fully active (Fig. 2). The loss of efﬁcacy in presence of
iron sulfate indicates that the compounds chelate iron which in
turn either inactivates the compounds or compensates for com-
pound induced iron deprivation in Chlamydia [9,17].
The salicylidene acylhydrazides (e.g. I, Fig. 1) are inhibitors of
T3S in a number of gram-negative pathogens including Chlamydia
spp. and Yersinia pseudotuberculosis [25]. T3S is a virulence system
in many clinically relevant gram-negative bacteria that allows
direct transfer of bacterial effector proteins, toxins, into the host cell
and thereby promotes bacterial survival. Compounds 11aed and
15aed contain salicylidene acylhydrazide functional groups and
inhibition of T3S in Y. pseudotuberculosiswas evaluated using a yopE
luciferase reporter gene assay and an orthogonal assay that mea-
sures phosphatase activity of the secreted YopH effector proteins as
described previously [18]. As expected both the 11aed and 15aed
series inhibited T3S in a dose-dependent fashion (Figs. 3 and 4). The
most potent compound 11d almost completely blocked the yopE-
luxAB reporter signal at 100 mM and (Fig. 3) with concomitant
reduction of the phosphatase activity of secreted YopH (Fig. 4). The
Table 1
Antichlamydial activity of synthesized compounds.
ID Structure Inhibition (%)a ID Structure Inhibition (%)a
C. t.b C. p.c C. t.b C. p.c
4a 18.5 NAd 11a 47.4 NA
4b NA NA 11b 24.2 NA
4c 9.6 NA 11c 83.0 100
4d 14.8 NA 11d 65.2 99.4
5a 26.9 NA 15a 33.4 NA
5b NA NA 15b 14.6 NA
5c NA 60.8 15c 28.0 22.4
5d 26.9 NA 15d 21.5 NA
a Percent inhibition at 50 mM.
b Chlamydia trachomatis.
c Chlamydia pnemoniae.
d NA: not active.
Fig. 2. Inhibition of C. trachomatis growth by compounds 11c, 11d and the acylated
sulfonamide 16 at 50 mM concentration in presence of 0.08e250 mM iron in the me-
dium. Data processed with GrapPadPrism 6.0, transformed to logarithmic scale and
curve ﬁtted, mean and SD are shown (n ¼ 3).
Fig. 3. Inhibition of T3S yopE luciferase reporter gene assay in Y. pseudotuberculosis
cultures. Percent inhibition compared to controls treated with 1% DMSO.
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the two assays at 100 mM (data not shown) and although some
growth inhibition Y. pseudotuberculosis was seen at the highestconcentration. All compounds had minimum inhibition concen-
tration (MIC) values above 100 mM indicating that general growth
inhibition is not the underlying reason for the observed T3S
inhibition.
Compounds 11c and 11d block T3S in Y. pseudotuberculosis,
prevent intracellular growth of Chlamydiae in a fashion that can be
blocked by excess iron and thus fullﬁll the design criteria. Themode
of action for the sulfonamides e.g. 16 is unknown and although 11c
Fig. 4. Reduction of the phosphatse actvity of the secreted YopH effector protein in
Y. pseudotuberculosis cultures. Percent inhibition compared to controls treated with 1%
DMSO.
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conﬁrm that the observed inhibition of Chlamydiae is the result of
all three mechanisms.
3. Conclusions
In conclusion the polypharmacological approach resulted in
novel antichlamydial molecular entities with rationally selected
properties, which could open new possibilities for antibiotic
development.
4. Experimental
4.1. General
All reagents and solvents were used as received from commer-
cial suppliers, unless indicated otherwise. DMF and THF were dried
in a solvent drying system (drying agent: neutral alumina) and
collected fresh prior to every reaction. Pyridine and 1,4-dioxane
were dried over 4 Å molecular sieves. TLC was performed on
aluminum backed silica gel plates (median pore size 60 Å, ﬂuo-
rescent indicator 254 nm) and detected with UV light at 254 nM.
Column chromatography was performed using silica gel with an
average particle diameter 50 mm (range 40e65 mm, pore diameter
53 Å). LC-MS was carried out with a Waters LC system equipped
with an Xterra C18 column (50 19mm, 5 mm,125 Å), elutedwith a
linear gradient of acetonitrile in water, both of which contained
formic acid (0.2%). A ﬂow rate of 1.5mL/minwas used and detection
was performed at 254 nm. Mass spectra were obtained on a Water
micromass ZQ 2000 using positive and negative electrospray
ionization. 1H NMR and 13C NMR spectra were recorded with a
Bruker DRX-400 or Bruker DRX-600spectrometer. NMR experi-
ments were conducted in DMSO-d6 and CH3OH-d4. HRMS was
performed by using a mass spectrometer with ESI-TOF (ESþ); so-
dium formate was used as the calibration chemical. All target
compounds were 97% pure according to 1H NMR and HRMS data.
4.2. Procedure for the synthesis of compound 2
A mixture of 4-acetamidobenzene-1-sulfonyl chloride
(4.27 mmol), 5-methylisoxazol-3-amine (4.49 mmol) and DMAP
(0.21 mmol) in anhydrous pyridine (10 mL) was stirred at room
temperature for 12 h. After completion of reaction, solvent was
evaporated to dryness and diluted with water and extracted with
ethyl acetate. The combined organic layers were washed withwater and 1 M aqueous HCl, dried over anhydrous Na2SO4, ﬁltered,
and concentrated under vacuum. The solid residue obtained was
puriﬁed with ﬂash column chromatography using heptanes to
EtOAc (50e100%) gradient elution to afford the compound 2.
4.2.1. N-(4-(N-(5-Methylisoxazol-3-yl)sulfamoyl)phenyl)acetamide
(2)
Yield: 59%; ESIMS m/z calcd for C12H13N3O4S [M þ H]þ, 296.07;
found 296.06; 1H NMR (400 MHz, (CD3)2SO): d 11.30 (bs, 1H), 10.35
(bs, 1H), 7.79e7.73 (m, 4H), 6.12 (s, 1H), 2.29 (s, 3H), 2.07 (s, 3H). 13C
(100MHz, (CD3)2SO): d 170.71,169.57,158.07,144.01,133.36,128.50,
119.15, 95.84, 24.57, 12.48.
4.3. Procedure for the synthesis of compound 3
To the intermediate 2 (2.53 mmol) suspended in water (15 mL)
was added NaOH (31.7 mmol) and reﬂuxed for 4 h to generate a
yellow solution. This was acidiﬁed to pH 5.5 at 70e80 C with 2 M
HCl. After cooling it to room temperature precipitates formed were
collected, washed with H2O and dried to obtain the compound 3.
4.3.1. 4-Amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide (3)
Yield: 93%; ESIMS m/z calcd for C10H11N3O3S [M þ H]þ, 254.06;
found 254.11; 1H NMR (400 MHz, (CD3)2SO): d 10.91 (bs, 1H), 7.46
(d, 2H, J ¼ 8.76 Hz), 6.58 (d, 2H, J ¼ 8.80 Hz), 6.08 (s, 1H), 6.07 (bs,
2H), 2.29 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.33, 158.41, 153.76,
129.29, 124.58, 113.05, 95.76, 12.48.
4.4. General procedure for the synthesis of compounds 4aed
To a stirred solution of compound 3 (0.98 mmol) in dry THF
(10 mL) at 0 C under nitrogen was added DIPEA (1.13 mmol) fol-
lowed by triphosgene (0.39 mmol) and continued stirring for 1 h
and for 2 h at room temperature. At this point of time, respective
amines (1.07 mmol) were added and allowed to stir at room tem-
perature for 12 h. The reaction mixture was evaporated to dryness
and diluted with water, extracted with EtOAc, dried over anhyd.
Na2SO4 and concentrated under vacuum. The obtained residues
were puriﬁedwith ﬂash column chromatography using heptanes to
EtOAc (20e40%) gradient elution to afford the compounds 4aed in
respective yields.
4.4.1. 4-(3-Benzylureido)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide (4a)
Yield: 29%; ESIMS m/z calcd for C18H18N4O4S [M þ H]þ, 387.11;
found 387.03; 1H NMR (400 MHz, (CD3)2SO): d 11.22 (s, 1H), 9.08 (s,
1H), 7.70 (d, 2H, J¼ 8.92 Hz), 7.57 (d, 2H, J¼ 9.00 Hz), 7.35e7.24 (m,
5H), 6.82 (t, 1H, J ¼ 5.96 Hz), 6.11 (s, 1H), 4.30 (d, 2H, J ¼ 5.92 Hz),
2.29 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.64, 158.14, 155.17,
145.47, 140.42, 131.22, 128.79, 128.56, 127.59, 127.26, 117.58, 95.81,
43.21, 12.51; HRMS (ES): m/z calcd for C18H18N4O4S [M þ Na]þ,
409.0941; found 409.0942.
4.4.2. 4-(3-(2-Hydroxybenzyl)ureido)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide (4b)
Yield: 30%; ESIMS m/z calcd for C18H18N4O5S [M þ H]þ, 403.11;
found 403.02; 1H NMR (400 MHz, (CD3)2SO): d 11.21 (bs, 1H), 9.59
(s, 1H), 9.11 (s, 1H), 7.69 (d, 2H, J¼ 8.84 Hz), 7.55 (d, 2H, J¼ 8.84 Hz),
7.14 (d, 1H, J ¼ 7.44 Hz), 7.10e7.06 (m, 1H), 6.81 (d, 1H, J ¼ 7.96 Hz),
6.75 (t, 1H, J ¼ 7.40 Hz), 6.64 (t, 1H, J¼ 5.82 Hz), 6.10 (s, 1H), 4.22 (d,
2H, J ¼ 5.80 Hz), 2.28 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.63,
158.14, 155.51, 155.23, 145.45, 131.18, 129.16, 128.58, 128.55, 126.01,
119.30, 117.47, 115.41, 95.81, 39.00, 12.51; HRMS (ES): m/z calcd for
C18H18N4O5S [M þ Na]þ, 425.0890; found 425.0896.
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benzenesulfonamide (4c)
Yield: 29%; ESIMS m/z calcd for C17H16N4O5S [M þ H]þ, 389.09;
found 389.11; 1H NMR (400MHz, (CD3)2SO): d 11.25 (bs,1H), 9.12 (s,
1H), 9.03 (s, 1H), 8.49 (s, 1H), 7.73 (d, 2H, J ¼ 8.84 Hz), 7.60 (d, 2H,
J ¼ 8.88 Hz), 7.22 (d, 2H, J ¼ 8.80 Hz), 6.69 (d, 2H, J ¼ 8.80 Hz), 6.12
(s, 1H), 2.29 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.68, 158.13,
153.41, 152.81, 145.06, 131.62, 130.96, 128.60, 121.26, 117.93, 115.72,
95.83, 12.51; HRMS (ES): m/z calcd for C17H16N4O5S [M þ Na]þ,
411.0734; found 411.0738.
4.4.4. 4-(3-Cyclohexylureido)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide (4d)
Yield: 16%; ESIMS m/z calcd for C17H22N4O4S [M þ H]þ, 379.14;
found 379.04; 1H NMR (400 MHz, (CD3)2SO): d 11.20 (bs, 1H), 8.78
(s, 1H), 7.67 (d, 2H, J¼ 8.84 Hz), 7.52 (d, 2H, J¼ 8.88 Hz), 6.26 (d, 1H,
J ¼ 8.80 Hz), 6.09 (s, 1H), 3.47e3.45 (m, 1H), 2.28 (s, 3H), 1.80e1.77
(m, 2H), 1.66e1.63 (m, 2H), 1.55e1.52 (m, 1H), 1.34e1.26 (m, 2H),
1.21e1.13 (m, 3H). 13C (100MHz, (CD3)2SO): d 170.62, 158.16, 154.28,
145.53,131.02,128.57,117.35, 95.81, 48.18, 33.19, 25.64, 24.74,12.50;
HRMS (ES): m/z calcd for C17H22N4O4S [M þ Na]þ, 401.1254; found
401.1262.
4.5. General procedure for the synthesis of compounds 5aed
To a stirred solution of compound 3 (0.39 mmol) in dry THF
(2 mL) at 0 C under nitrogen atmosphere was added thiophosgene
(0.39 mmol) and continued stirring for 1 h. Reaction mixture was
warmed to room temperature and continued stirring for overnight.
The solvent was evaporated to dryness and the residue was sus-
pended in 1,4-dioxane (3 mL), to this was added triethylamine
(0.98mmol) followed by respective amines (0.39mmol) and stirred
at reﬂux for 12 h. The reaction mixture was evaporated to dryness
and the crude was puriﬁed by ﬂash column chromatography using
1e5% MeOH in dichloromethane gradient elution to afford the
compounds 5aed in respective yields.
4.5.1. 4-(3-Benzylthioureido)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide (5a)
Yield: 29%; ESIMSm/z calcd for C18H18N4O3S2 [M þ H]þ, 403.09;
found 402.96; 1H NMR (600 MHz, (CD3)2SO): d 11.34 (bs, 1H), 9.99
(bs, 1H), 8.52 (bs, 1H), 7.77e7.74 (m, 4H), 7.36e7.34 (m, 4H),
7.28e7.26 (m, 1H), 6.13 (s, 1H), 4.74 (d, 2H, J ¼ 4.86 Hz), 2.29 (s, 3H).
13C (100 MHz, (CD3)2SO): d 180.96, 170.70, 158.13, 144.60, 138.88,
133.77,128.81,128.01,127.51,121.86, 95.84, 47.64,12.54; HRMS (ES):
m/z calcd for C18H18N4O3S2 [M þ Na]þ, 425.0713; found 425.0709.
4.5.2. 4-(3-(2-Hydroxybenzyl)thioureido)-N-(5-methylisoxazol-3-
yl)benzenesulfonamide (5b)
Yield: 42%; ESIMSm/z calcd for C18H18N4O4S2 [M þ H]þ, 419.08;
found 419.00; 1H NMR (600 MHz, (CD3)2SO): d 11.33 (bs, 1H), 9.99
(bs, 1H), 9.66 (bs, 1H), 8.26 (bs, 1H), 7.80e7.73 (m, 4H), 7.19 (d, 1H,
J ¼ 7.32 Hz), 7.13e7.09 (m, 1H), 6.84 (d, 1H, J ¼ 7.84 Hz), 6.77 (t, 1H,
J ¼ 7.44 Hz), 6.13 (s, 1H), 4.63 (d, 2H, J ¼ 4.48 Hz), 2.29 (s, 3H). 13C
(100 MHz, (CD3)2SO): d 180.57, 170.65, 158.22, 155.64, 144.73,
133.63, 129.65, 128.81, 127.95, 124.40, 121.46, 119.27, 115.39, 95.86,
43.48, 12.54; HRMS (ES): m/z calcd for C18H18N4O4S2 [M þ Na]þ,
441.0662; found 441.0667.
4.5.3. 4-(3-(4-Hydroxyphenyl)thioureido)-N-(5-methylisoxazol-3-
yl)benzenesulfonamide (5c)
Yield: 14%; ESIMSm/z calcd for C17H16N4O4S2 [M þ H]þ, 405.07;
found 404.91; 1H NMR (400 MHz, (CD3)2SO): d 11.35 (bs, 1H), 9.89
(bs, 1H), 9.86 (bs, 1H), 9.41 (s, 1H), 7.77e7.71 (m, 4H), 7.18 (d, 2H,
J ¼ 8.76 Hz), 6.73 (d, 2H, J ¼ 8.80 Hz), 6.14 (s, 1H), 2.30 (s, 3H). 13C(100 MHz, (CD3)2SO): d 179.99, 170.69, 158.17, 155.60, 144.83,
134.03, 130.57, 127.78, 126.62, 122.68, 115.58, 95.86, 12.55; HRMS
(ES): m/z calcd for C17H16N4O4S2 [M þ Na]þ, 427.0505; found
427.0507.
4.5.4. 4-(3-Cyclohexylthioureido)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide (5d)
Yield: 45%; ESIMSm/z calcd for C17H22N4O3S2 [M þ H]þ, 395.12;
found 395.09; 1H NMR (600 MHz, (CD3)2SO): d 11.32 (bs, 1H), 9.72
(bs, 1H), 8.03 (bs, 1H), 7.74 (s, 4H), 6.14 (s, 1H), 4.09 (m, 1H), 2.30 (s,
3H), 1.92e1.90 (m, 2H), 1.70e1.68 (m, 2H), 1.58e1.56 (m, 1H),
1.33e1.16 (m, 5H). 13C (100MHz, (CD3)2SO): d 179.25,170.71,158.09,
144.87, 133.29, 127.95, 121.29, 95.83, 52.69, 32.05, 25.58, 24.90,
12.53; HRMS (ES):m/z calcd for C17H22N4O3S2 [M þ Na]þ, 417.1026;
found 417.1030.
4.6. Procedure for the synthesis of compound 7
A mixture of 4-bromobenzene-1-sulfonyl chloride (20.3 mmol),
5-methylisoxazol-3-amine (20.3 mmol) and DMAP (0.20 mmol) in
anhydrous pyridine (25 mL) was stirred for 12 h at room temper-
ature. The reaction mixture was poured on to crushed ice and
extracted with EtOAc. The organic layer was washed with water
and 1 M HCl, dried over anhydrous Na2SO4, ﬁltered, and concen-
trated under vacuum. The solid residue obtained was dissolved in
EtOAc and triturated with heptanes. The precipitate formed was
ﬁltered and dried under vacuum to obtain the compound 7.
4.6.1. 4-Bromo-N-(5-methylisoxazol-3-yl)benzenesulfonamide (7)
Yield: 74%; ESIMSm/z calcd for C10H9BrN2O3S [M þ H]þ, 316.95;
found 316.81; 1H NMR (600 MHz, (CD3)2SO): d 11.56 (bs, 1H), 7.84
(d, 2H, J¼ 8.70 Hz), 7.78 (d, 2H, J¼ 8.64 Hz), 6.14 (s,1H), 2.30 (s, 3H).
13C (100 MHz, (CD3)2SO): d 171.01, 157.76, 139.11, 133.00, 129.21,
127.84, 95.91, 12.51.
4.7. Procedure for the synthesis of compound 8
Compound 7 (6.30 mmol), Pd2(dba)3 (0.31 mmol), dppf
(0.63 mmol), Zn powder (0.75 mmol) and Zn(CN)2 (3.78 mmol)
were placed in a dry argon ﬂushed ﬂask. To this was added dry DMF
(20 mL) via syringe. The resulting mixture was stirred for 18 h at
150 C under argon. The reaction mixture was cooled to room
temperature and dilutedwith EtOAc. The organic phasewas ﬁltered
through celite, and thenwashedwith 2 N aqueous NH3 solution and
with water, dried over Na2SO4 and concentrated. The crude was
puriﬁed by ﬂash column chromatography using 20e30% EtOAc in
heptanes gradient elution to afford the compound 8.
4.7.1. 4-Cyano-N-(5-methylisoxazol-3-yl)benzenesulfonamide (8)
Yield: 36%; ESIMS m/z calcd C11H9N3O3S [M þ H]þ, 264.04;
found 264.04; 1H NMR (400 MHz, CDCl3): d 9.79 (bs, 1H), 8.07 (d,
2H, J ¼ 8.68 Hz), 7.79 (d, 2H, J ¼ 8.64 Hz), 6.54 (s, 1H), 2.23 (s, 3H).
13C (100 MHz, CDCl3): d 156.75, 146.42, 142.34, 132.72, 127.09,
117.59, 115.78, 109.37, 10.90.
4.8. Procedure for the synthesis of compound 9
To the compound 8 (3.41 mmol) suspended in a mixture of 2-
propanol (25 mL) and water (20 mL) was added KOH (102 mmol)
and heated to 100 C for 18 h. The reaction mixture was cooled to
ambient temperature and evaporated to remove 2-propanol. Crude
was diluted with water and washed with EtOAc. The aqueous layer
was acidiﬁed with 2 M HCl to pH 2e3, and extracted with EtOAc,
dried over Na2SO4 and concentrated to dryness to obtain the
desired compound 9.
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Yield: 98%; ESIMS m/z calcd for C11H10N2O5S [M þ H]þ, 283.04;
found 283.10; 1H NMR (400 MHz, (CD3)2SO): d 13.23 (bs, 1H), 11.95
(bs, 1H), 8.07 (d, 2H, J ¼ 8.56 Hz), 7.95 (d, 2H, J ¼ 8.60 Hz), 6.91 (s,
1H), 2.12 (s, 3H). 13C (100 MHz, (CD3)2SO): d 166.80, 156.26, 147.20,
142.23, 134.06, 130.32, 126.69, 110.97, 10.87.4.9. Procedure for the synthesis of compound 10a
To a stirred solution of compound 9 (3.36 mmol) in dry DMF
(10 mL) was added DMAP (0.16 mmol), EDC$HCl (4.03 mmol) fol-
lowed by tert-butyl carbazate (4.03 mmol). The resulting mixture
was stirred for 12 h at room temperature under nitrogen. The re-
action mixture was diluted with water, extracted with EtOAc, dried
over Na2SO4 and concentrated. The crude residue was dissolved in
EtOAc and triturated with heptanes. The precipitate formed was
ﬁltered and dried under vacuum to afford compound 10a.4.9.1. tert-Butyl 2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)
benzoyl)hydrazinecarboxylate (10a)
Yield: 75%; ESIMS m/z calcd for C16H20N4O6S [M þ H]þ, 397.07;
found 397.04; 1H NMR (400 MHz, (CD3)2SO): d 11.88 (bs, 1H), 10.35
(s, 1H), 8.99 (s, 1H), 7.94 (m, 4H), 6.89 (s, 1H), 2.11 (s, 3H), 1.43 (s,
9H). 13C (100 MHz, (CD3)2SO): d 165.65, 156.37, 155.82, 146.30,
142.14, 135.92, 128.42, 126.61, 111.19, 79.80, 28.54, 10.89.4.10. Procedure for the synthesis of compound 10b
To a stirred solution of compound 10a (2.52mmol) in 10%MeOH
in DCM (10 mL) at 0 C, was added 4 M HCl in 1,4-dioxane solution
(10 mL) drop wise under nitrogen. The resulting mixture was stir-
red for overnight at ambient temperature under nitrogen. The
precipitate formed was ﬁltered and dried under vacuum under
nitrogen to afford compound 10b.4.10.1. 4-(Hydrazinecarbonyl)-N-(5-methylisoxazol-3-yl)
benzenesulfonamide hydrochloride (10b)
Yield: 83%; ESIMS m/z calcd for C11H13ClN4O4S [M þ HeHCl]þ,
297.07; found 297.00; 1H NMR (400 MHz, (CD3)2SO): d 11.95 (bs,
1H),11.77 (bs,1H), 8.05e7.98 (m, 4H), 6.92 (s,1H), 3.68 (bs, 2H), 2.12
(s, 3H). 13C (100 MHz, (CD3)2SO): d 165.26, 156.15, 147.04, 142.29,
133.67, 129.01, 126.73, 111.01, 10.90.4.11. General procedure for the synthesis of compounds 11aed
A mixture of compound 10b (0.21 mmol) and respective sali-
cylaldehyde (0.24mmol) in EtOH (5mL) was heated to 70 C for 4 h.
The precipitate formed was ﬁltered when the reaction is hot,
washed with hot EtOH (2  5 mL) and dried under vacuum to
obtain the compounds 11aed in respective yields.4.11.1. (E)-4-(2-(2,4-Dihydroxybenzylidene)hydrazinecarbonyl)-N-
(5-methylisoxazol-3-yl)benzenesulfonamide (11a)
Yield: 52%; ESIMS m/z calcd for C18H16N4O6S [M þ H]þ, 417.09;
found 416.99; 1H NMR (400 MHz, (CD3)2SO): d 12.03 (s, 1H), 11.90
(bs, 1H), 11.35 (s, 1H), 9.99 (s, 1H), 8.51 (s, 1H), 8.04 (d, 2H,
J ¼ 8.60 Hz), 7.98 (d, 2H, J ¼ 8.60 Hz), 7.34 (d, 1H, J ¼ 8.52 Hz), 6.91
(s, 1H), 6.38e6.32 (m, 2H), 2.12 (s, 3H). 13C (100 MHz, (CD3)2SO):
d 161.95,161.36,159.97,156.30,150.01,146.17, 142.20, 136.42, 131.73,
128.66, 126.60, 110.96, 108.25, 103.11, 10.89; HRMS (ES): m/z calcd
for C18H16N4O6S [M þ Na]þ, 439.0683; found 439.0689.4.11.2. (E)-4-(2-(3,5-Dichloro-2-hydroxybenzylidene)
hydrazinecarbonyl)-N-(5-methylisoxazol-3-yl)-
benzenesulfonamide (11b)
Yield: 55%; ESIMS m/z calcd for C18H14Cl2N4O5S [M þ Hþ]þ,
469.01; found 468.80; 1H NMR (600MHz, (CD3)2SO): d 12.64 (s,1H),
12.40 (s, 1H), 11.92 (bs, 1H), 8.59 (s, 1H), 8.08 (d, 2H, J ¼ 6.96 Hz),
8.01 (d, 2H, J¼ 6.84 Hz), 7.70 (s, 1H), 7.64 (s, 1H), 6.92 (s, 1H), 2.12 (s,
3H). 13C (150 MHz, (CD3)2SO): d 162.57, 156.29, 152.74, 147.97,
146.63,142.25,135.58,130.92,128.92,126.70,123.49,122.03,121.25,
110.99, 10.89; HRMS (ES): m/z calcd for C18H14Cl2N4O5S [M þ Na]þ,
490.9954; found 490.9949.
4.11.3. (E)-4-(2-(4-(Diethylamino)-2-hydroxybenzylidene)
hydrazinecarbonyl)-N-(5-methylisoxazol-3-yl)-
benzenesulfonamide (11c)
Yield: 40%; ESIMS m/z calcd for C22H25N5O5S [M þ H]þ, 472.16;
found 472.07; 1H NMR (400 MHz, (CD3)2SO): d 11.91 (s, 1H), 11.89
(bs, 1H), 11.35 (s, 1H), 8.42 (s, 1H), 8.02 (d, 2H, J ¼ 8.64 Hz), 7.97 (d,
2H, J ¼ 8.64 Hz), 7.22 (d, 1H, J ¼ 8.88 Hz), 6.88 (s, 1H), 6.28 (dd, 1H,
J ¼ 8.84, 2.40 Hz), 6.13 (d, 1H, J ¼ 2.40 Hz), 3.39e3.34 (m, 4H), 2.12
(s, 3H), 1.11 (t, 6H, J ¼ 7.02 Hz). 13C (150 MHz, (CD3)2SO): d 161.65,
160.22, 156.38, 150.85, 150.77, 146.10, 142.15, 136.56, 132.09, 128.56,
126.59, 111.14, 106.81, 104.19, 97.92, 44.27, 13.01, 10.90; HRMS (ES):
m/z calcd for C22H25N5O5S [M þ Na]þ, 494.1469; found 494.1464.
4.11.4. (E)-4-(2-(3,5-Dibromo-2-hydroxybenzylidene)
hydrazinecarbonyl)-N-(5-methylisoxazol-3-yl)-
benzenesulfonamide (11d)
Yield: 39%; ESIMS m/z calcd for C18H14Br2N4O5S [M þ H]þ,
556.91; found 556.82; 1H NMR (600MHz, (CD3)2SO): d 12.68 (s,1H),
12.63 (s, 1H), 11.92 (bs, 1H), 8.55 (s, 1H), 8.08 (d, 2H, J ¼ 8.34 Hz),
8.01 (d, 2H, J ¼ 8.34 Hz), 7.84 (s, 2H), 6.92 (s, 1H), 2.12 (s, 3H). 13C
(150MHz, (CD3)2SO): d 162.57,156.29,154.15, 148.11,146.64, 142.25,
136.22, 135.52, 132.66, 128.94, 126.70, 121.41, 111.76, 110.98, 110.95,
10.89; HRMS (ES): m/z calcd for C18H14Br2N4O5S [M þ Na]þ,
578.8944; found 578.8934.
4.12. Procedure for the synthesis of compound 12
To a stirred solution of compound 3 (7.89 mmol) in dry THF
(20 mL) at 0 C under nitrogen, was added NaH (8.28 mmol) and
continued stirring for 30 min. To this reaction mixture acryloyl
chloride (8.28 mmol) was added drop wise and stirred at same
temperature for 1 h and 4 h at room temperature. Excess NaH was
quenched with little methanol water mixture (1:1). The reaction
mixture was diluted with water and extracted with EtOAc. The
organic layer was dried over Na2SO4 and concentrated. The crude
was puriﬁed by column chromatography using 10e30% EtOAc in
heptanes as an eluent to obtain compound 12.
4.12.1. N-(4-(N-(5-Methylisoxazol-3-yl)sulfamoyl)phenyl)
acrylamide (12)
Yield: 47%; ESIMS m/z calcd for C13H13N3O4S [M þ H]þ, 308.07;
found 308.07; 1H NMR (400 MHz, (CD3)2SO): d 11.37 (bs, 1H), 11.00
(bs, 1H), 7.92 (d, 2H, J¼ 8.88 Hz), 7.80 (d, 2H, J¼ 8.88 Hz), 6.61e6.54
(m, 1H), 6.29 (dd, 1H, J ¼ 17.40, 1.80 Hz), 6.13 (s, 1H), 5.80 (dd, 1H,
J ¼ 10.16, 1.82 Hz), 2.29 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.70,
164.26, 158.02, 143.94, 133.71, 132.00, 128.45, 128.29, 119.60, 95.85,
12.52.
4.13. Procedure for the synthesis of compound 13
To a stirred solution of 4-bromobenzoic acid (9.94 mmol) in dry
DMF (20 mL) was added DMAP (0.49mmol), EDC$HCl (11.94mmol)
followed by tert-butyl carbazate (11.94 mmol). The resulting
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mosphere. The reaction mixture was diluted with water, extracted
with EtOAc, dried over Na2SO4 and concentrated. The crude residue
was dissolved in EtOAc and triturated with heptanes. The precipi-
tate formed was ﬁltered and dried under vacuum to afford com-
pound 13.
4.13.1. tert-Butyl 2-(4-bromobenzoyl)hydrazinecarboxylate (13)
Yield: 45%; ESIMSm/z calcd for C12H15BrN2O3 [M þ H]þ, 315.03;
found 314.99.; 1H NMR (400 MHz, (CD3)2SO): d 10.28 (bs, 1H), 8.94
(bs, 1H), 7.79 (d, 2H, J¼ 8.32 Hz), 7.71 (dd, 2H, J¼ 6.72, 1.88 Hz), 1.43
(s, 9H). 13C (100 MHz, (CD3)2SO): d 165.61, 155.88, 132.10, 132.00,
129.92, 126.04, 79.74, 28.55.
4.14. Procedure for the synthesis of compound 14a
To a stirred solution of Compound 13 (2.53 mmol) and com-
pound 12 (3.04 mmol) in dry DMF (10 mL), was added TEA
(3.80 mmol), Pd(OAc)2 (0.25 mmol) followed by diphenylphos-
phinopropane (0.25 mmol) under nitrogen. The mixture was
heated to 100 C and continued stirring for 24 h under nitrogen
atmosphere. The reaction mixture was cooled down to room tem-
perature, diluted with water and extracted with EtOAc. The organic
layer was dried over Na2SO4 and concentrated. The crude mixture
was suspended in EtOAc and sonicated for 15 min. The precipitate
formed was ﬁltered, washed with hot EtOAc and dried under vac-
uum to obtain compound 14a.
4.14.1. (E)-tert-Butyl 2-(4-(3-((4-(N-(5-methylisoxazol-3-yl)
sulfamoyl)phenyl)amino)-3-oxoprop-1-en-1-yl)benzoyl)
hydrazinecarboxylate (14a)
Yield: 29%; ESIMS m/z calcd for C25H27N5O7S [MH]þ, 540.16;
found 540.01; 1H NMR (400 MHz, (CD3)2SO): d 11.35 (bs, 1H), 10.66
(bs, 1H), 10.27 (bs, 1H), 8.95 (bs, 1H), 7.93e7.81 (m, 6H), 7.75 (d, 2H,
J¼ 8.40 Hz), 7.68 (d,1H, J¼ 15.72 Hz), 6.93 (d,1H, J¼ 15.80 Hz), 6.12
(s, 1H), 2.29 (s, 3H), 1.44 (s, 9H). 13C (100 MHz, (CD3)2SO): d 170.54,
165.87, 164.28, 158.43, 155.92, 143.69, 140.53, 138.10, 134.25, 133.91,
128.54, 128.33, 124.05, 119.53, 95.93, 79.73, 28.56, 12.52.
4.15. Procedure for the synthesis of compound 14b
To the suspension of compound 14a (0.73 mmol) in MeOH
(4 mL) at 0 C, was added 4 M HCl in 1,4-dioxane solution (8 mL)
drop wise under nitrogen. The resulting mixture was stirred for
overnight at ambient temperature under nitrogen. The precipitate
formed was ﬁltered and dried under vacuum under nitrogen to
afford compound 14b.
4.15.1. (E)-3-(4-(Hydrazinecarbonyl)phenyl)-N-(4-(N-(5-
methylisoxazol-3-yl)sulfamoyl)phenyl)acrylamide
hydrochloride (14b)
Yield: 90%; ESIMS m/z calcd for C20H20ClN5O5S [M þ HeHCl]þ,
442.12; found 441.98; 1H NMR (400 MHz, (CD3OD)): d 7.94 (d, 2H,
J ¼ 8.40 Hz), 7.87 (m, 4H), 7.79e7.73 (m, 3H), 6.91 (d, 1H,
J ¼ 15.72 Hz), 6.14 (s, 1H), 2.32 (s, 3H). 13C (100 MHz, (CD3)2SO):
d 170.75, 165.79, 164.27, 158.02, 143.95, 140.11, 139.11, 133.77, 131.71,
128.91, 128.56, 128.48, 124.75, 119.55, 95.86, 12.53.
4.16. General procedure for the synthesis of compounds 15aed
A mixture of compound 14b (0.20 mmol) and respective sali-
cylaldehyde (0.21mmol) in EtOH (5mL) was heated to 70 C for 4 h.
The precipitate formed was ﬁltered when the reaction is hot,
washed with hot EtOH (2  5 mL) and dried under vacuum to
obtain the compounds 15aed in respective yields.4.16.1. (E)-3-(4-((E)-2-(3-Fluoro-2-hydroxybenzylidene)
hydrazinecarbonyl)phenyl)-N-(4-(N-(5-methylisoxazol-3-yl)
sulfamoyl)phenyl)acrylamide (15a)
Yield: 34%; ESIMSm/z calcd for C27H22FN5O6S [M þ H]þ, 564.14;
found 563.94; 1H NMR (400 MHz, (CD3)2SO): d 12.16 (bs, 1H), 11.51
(bs, 1H), 11.17 (bs, 1H), 10.53 (s, 1H), 8.68 (s, 1H), 8.02 (d, 2H,
J¼ 7.00 Hz), 7.89e7.79 (m, 6H), 7.71 (d,1H, J¼ 15.64 Hz), 7.38 (d,1H,
J ¼ 7.76 Hz), 7.27 (t, 1H, J ¼ 9.46 Hz), 6.98e6.90 (m, 2H), 6.10 (s, 1H),
2.30 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.76, 164.27, 162.74,
158.04, 152.17, 150.57, 148.20, 145.83, 145.74, 143.85, 140.50, 138.43,
133.91, 133.85, 128.88, 128.61, 128.45, 125.36, 124.20, 121.65, 119.74,
119.69, 119.58, 118.11, 117.99, 95.86, 12.53; HRMS (ES):m/z calcd for
C27H22FN5O6S [M þ Na]þ, 586.1167; found 586.1164.
4.16.2. (E)-3-(4-((E)-2-(3,5-Dichloro-2-hydroxybenzylidene)
hydrazinecarbonyl)phenyl)-N-(4-(N-(5-methylisoxazol-3-yl)
sulfamoyl)phenyl)acrylamide (15b)
Yield: 39%; ESIMS m/z calcd for C27H21Cl2N5O6S [M þ H]þ,
614.07; found 613.81; 1H NMR (600MHz, (CD3)2SO): d 12.58 (s, 1H),
12.49 (s, 1H), 11.36 (s, 1H), 10.73 (s, 1H), 8.60 (s, 1H), 8.03 (d, 2H,
J ¼ 6.90 Hz), 7.90 (d, 2H, J ¼ 7.92 Hz), 7.85e7.81 (m, 4H), 7.72e7.62
(m, 3H), 6.97 (d, 1H, J ¼ 15.42 Hz), 6.15 (s, 1H), 2.30 (s, 3H). 13C
(150 MHz, (CD3)2SO): d 170.77, 164.25, 162.85, 158.02, 152.75,
147.62, 143.86, 140.44, 138.62, 133.82, 133.47, 130.80, 128.97, 128.90,
128.61, 128.45, 124.31, 123.43, 121.97, 121.25, 119.58, 95.86, 12.54;
HRMS (ES): m/z calcd for C27H21Cl2N5O6S [M þ Na]þ, 636.0482;
found 636.0477.
4.16.3. (E)-3-(4-((E)-2-(4-(Diethylamino)-2-hydroxybenzylidene)
hydrazinecarbonyl)phenyl)-N-(4-(N-(5-methylisoxazol-3-yl)
sulfamoyl)phenyl)acrylamide (15c)
Yield: 54%; ESIMS m/z calcd for C31H32N6O6S [M þ H]þ, 617.22;
found 616.96; 1H NMR (400 MHz, (CD3)2SO): d 11.89 (bs, 1H), 11.36
(bs, 2H), 10.72 (s, 1H), 8.45 (s, 1H), 7.99 (d, 2H, J ¼ 8.32 Hz), 7.90 (d,
2H, J ¼ 9.00 Hz), 7.85e7.78 (m, 4H), 7.70 (d, 1H, J ¼ 15.68 Hz),
7.23e7.21 (m,1H), 6.96 (d, 1H, J¼ 15.76 Hz), 6.30e6.28 (m,1H), 6.14
(s, 1H), 3.40e3.37 (m, 4H), 2.30 (s, 3H), 1.11 (t, 6H, J ¼ 6.98 Hz). 13C
(100 MHz, (CD3)2SO): d 170.76, 164.33, 162.24, 158.03, 143.93,
140.51, 138.12, 134.31, 133.78, 132.12, 128.73, 128.60, 128.37, 124.07,
119.56, 95.86, 44.61, 12.89, 12.53; HRMS (ES): m/z calcd for
C31H32N6O6S [M þ Na]þ, 639.1996; found 639.1989.
4.16.4. (E)-3-(4-((E)-2-(5-Bromo-2-hydroxybenzylidene)
hydrazinecarbonyl)phenyl)-N-(4-(N-(5-methylisoxazol-3-yl)
sulfamoyl)phenyl)acrylamide (15d)
Yield: 46%; ESIMS m/z calcd for C27H22BrN5O6S [M þ H]þ,
624.05; found 623.64; 1H NMR (600 MHz, (CD3)2SO): d 12.25 (bs,
1H), 11.35 (s, 1H), 11.26 (bs, 1H), 10.72 (bs, 1H), 8.64 (s, 1H), 8.02 (d,
2H, J ¼ 7.44 Hz), 7.90 (d, 2H, J ¼ 8.10 Hz), 7.85e7.80 (m, 5H), 7.70 (d,
1H, J¼ 15.66 Hz), 7.44 (d,1H, J¼ 7.62 Hz), 6.98e6.91 (m, 2H), 6.14 (s,
1H), 2.30 (s, 3H). 13C (100 MHz, (CD3)2SO): d 170.77, 164.28, 162.77,
158.02, 156.90, 146.20, 143.87, 140.51, 138.34, 134.12, 134.08, 133.81,
130.81, 128.88, 128.61, 128.40, 124.16, 121.82, 119.57, 119.17, 110.94,
95.86, 12.54; HRMS (ES): m/z calcd for C27H22BrN5O6S [M þ Na]þ,
646.0366; found 646.0350.
5. Biological assay methods
The synthesized compounds (4aed, 5aed, 11aed and 15aed)
were tested for growth inhibition of C. trachomatis and C. pneu-
moniae as previously described [12]. HeLa 229 cells (CCL-2.1, ATCC,
Manassas, VA) were infected independently with C. trachomatis L2
serovar (VR-902B, ATCC) and C. pneumoniae strain T45 [26]. The
synthesized compounds were dissolved in DMSO and two-fold
dilution series were used for the biological testing in 1% ﬁnal
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activity was evaluated with CellomicsArrayScanVTi HCS reader
(Thermo Scientiﬁc) automated microscope as described previously
[12]. Micrographs were generated at 100 magniﬁcation and the
Chlamydia inclusion number was automatically enumerated from
the micrographs at 24 h or 48 h post infection (p.i.). The most
potent compounds 11c& 11dwere analyzed for their iron chelation
property by adding the compounds at 50 mM with increasing
amounts of iron sulfate (Sigma) as described previously [9].
Effect of the compounds at 50 mM on host cell viability was
measured using resazurin as previously described [18] after incu-
bation of HeLa cells with compounds for 24 and 48 h in uncolored
RPMI with 0.5% DMSO. Resazurin (Sigma) was added to a ﬁnal
concentration of 40 mM 3 h prior to reading ﬂuorescence with
BioTek SynergyH4 (Winooski, VT, USA) plate reader (535/559 nm).
The series (11aed and 15aed) were also investigated for inhi-
bition of the Y. pseudotuberculosis type III secretion (T3S) system
using a luciferase reporter gene assay for Yersinia outer protein E
(yopE)and measurement of phosphatase activity of YopH in the
bacterial cultures [19,27] as previously described [22]. Compounds
were tested at two-fold dilutions from 100 mM to 12,5 mM and ﬁnal
DMSO concentration 1%. To test if the compounds inhibited growth
of Y. pseudotuberculosis, an overnight culture was diluted in Mueller
Hinton broth with 100, 50, 25, 12 mM compounds and incubated at
37 C for 20 h before bacterial growth was determined by visual
inspection. Unless otherwise stated all biological testing was per-
formed in triplicates, repeated at least on three separate days and
controls with DMSO alone were used.
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